Sermorelin 5mg

Sermorelin — Research Overview

Introduction

Sermorelin is a synthetic 29‐amino acid peptide corresponding to the N‐terminal portion of growth hormone–releasing hormone (GHRH). As a GHRH (1‐29) amide analog, it has been studied as the shortest fragment retaining biological activity at GHRH receptors [2–4].

Originally evaluated in the 1980s in rat models, Sermorelin was shown to stimulate pituitary growth hormone release and subsequently became a research tool for growth hormone deficiency paradigms [3,4]. Its pharmacological profile includes a short plasma half‐life of ~11–12 minutes, yet sufficient activity to elicit pulsatile GH secretion and downstream IGF‐1 responses [6].

Chemical Characteristics

Form: Lyophilized powder for reconstitution (research use)

Research Applications

1. GHRH Receptor Mechanisms

– Sermorelin binds GHRH receptors on pituitary somatotrophs, initiating cAMP‐PKA signaling cascades leading to GH secretion and IGF‐1 synthesis [12].

2. Growth Velocity Studies

– In pediatric GH deficiency models, Sermorelin exposure increased growth velocity and height gain sustained for up to 36 months [7].

3. Anabolic and Body Composition Outcomes

– Studies report GH elevations of ~82–107% and IGF‐1 increases of ~28%, associated with lean body mass gains and skin thickness increases [13,14].

4. Lipodystrophy Models

– In HIV‐positive lipodystrophy patients, Sermorelin increased GH and IGF‐1, improved lean mass, and reduced visceral/trunk fat ratios without altering glucose/insulin [8].

5. Cognition and Aging

– In elderly cohorts, Sermorelin administration improved WAIS test performance and other cognitive measures, consistent with GH/IGF‐1 support of cognition [9].

6. Tumor Cell Research

– Screening of glioma cells suggested Sermorelin sensitivity and potential cell‐cycle blocking effects, highlighting mechanistic interest in oncology [10].

7. Hypogonadism and Reproductive Hormones

– Studies exploring Sermorelin in hypogonadism reported stimulation of LH/FSH and testosterone trends, though elderly cohorts showed limited statistical significance [11].

Conclusion

Sermorelin is a 29‐amino acid GHRH analog retaining receptor activity sufficient to stimulate GH and IGF‐1. Research has examined its roles in growth velocity, body composition, lipodystrophy, cognition, tumor sensitivity, and hypogonadism. While mechanistic pathways are increasingly understood, applications remain restricted to controlled laboratory research [2–14].

Sermorelin — References

• Garcia, J. M., Merriam, G. R., & Kargi, A. Y. Growth Hormone in Aging. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. Updated 2019 Oct 7.https://www.ncbi.nlm.nih.gov/books/NBK279163/
• Prakash, A., & Goa, K. L. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2): 139–157.https://pubmed.ncbi.nlm.nih.gov/18031173/
• National Center for Biotechnology Information. PubChem Compound Summary for CID 16129620, Sermorelin. PubChem.https://pubchem.ncbi.nlm.nih.gov/compound/Sermorelin
• Clark, R. G., & Robinson, I. C. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008): 281–283.https://pubmed.ncbi.nlm.nih.gov/2858818/
• Drugs@FDA. FDA Approved Drug Products: Sermorelin.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
• Junichi, I. et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JSCM Rapid Communications. 2020;3(1).https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
• Koutkia, P., Canavan, B., Breu, J., Torriani, M., & Grinspoon, S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2): 210–218.https://pubmed.ncbi.nlm.nih.gov/15249570/
• Vitiello, M. V., Wilkinson, C. W., Merriam, G. R., Moe, K. E., Prinz, P. N., Ralph, D. D., & Schwartz, R. S. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiology of Aging. 2006;27(2): 318–323.https://pubmed.ncbi.nlm.nih.gov/16399214/
• Chang, Y., Zhuang, X., Zhang, J., Xu, L., Zhang, W., Zhu, X., & Xu, X. A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of Translational Medicine. 2021;9(5): 406.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033379/
• Sinha, D. K., Laughlin, G. A., & Yen, S. S. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2): S149–S159.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/
• Zhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., & Wang, M. W. Structural basis for activation of the growth hormone-releasing hormone receptor. Nature Communications. 2020;11(1): 5205.https://doi.org/10.1038/s41467-020-18945-0
• Vittone, J., Blackman, M. R., Busby-Whitehead, J., Tsiao, C., Stewart, K. J., Tobin, J., Stevens, T., Bellantoni, M. F., Rogers, M. A., Baumann, G., Roth, J., Harman, S. M., & Spencer, R. G. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1): 89–96.https://doi.org/10.1016/s0026-0495(97)90174-8
• Khorram, O., Laughlin, G. A., & Yen, S. S. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism. 1997;82(5): 1472–1479.https://doi.org/10.1210/jcem.82.5.3943

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.